FDA’s Predetermined Change Plans: SaMD’s Billion Dollar Impact

The old regulatory bottleneck for adaptive AI was a killer. For years, every time we wanted to push a small algorithmic tweak to improve patient outcomes, we had to go back to the FDA for a new premarket submission. Think about that. You’re looking at 142-151 days on average for a 510(k), and way longer for a De Novo (150-300 days) or a PMA (180+ days). That kind of delay just kills innovation and makes patients wait. The old framework was built for safety, which is good, but it actively discouraged the kind of rapid, real-world learning that makes Software as a Medical Device (SaMD) so effective.

PCCPs Are Here: FDA Finally Opens the Door for AI Updates

The game completely changed with the FDA’s December 2024 final guidance on Predetermined Change Control Plans FDA December 2024 final guidance on Predetermined Change Control Plans. This is the pathway we’ve been waiting for. It allows AI/ML-enabled medical devices, especially SaMD, to get pre-approval for a whole list of future modifications, all without a new submission for every single update. If you’re a VC in the space or a device exec, you have to get your head around PCCPs fast. They create a real regulatory moat that slashes post-market development costs and helps you grab market share faster. Developers can now get future updates pre-cleared. Instead of filing a new 510(k) every time you retrain an algorithm on new data or adjust a performance spec within an agreed-upon range, you can just execute the change under your approved plan. For adaptive cardiac AI, where the whole point is continuous learning from real-world evidence (RWE) to get more accurate, this is everything. Without a PCCP, a continuously learning AI model just doesn’t scale from a regulatory standpoint.

How AI Health Leaders Are Pushing Updates

Look at what companies like Digital Diagnostics and Cleerly have been doing to manage iterative updates, even before PCCPs were official. Digital Diagnostics got FDA clearances for its autonomous AI diagnostic systems by being incredibly rigorous with their validation and showing they deeply understood what the agency expected. Their work getting those clearances Digital Diagnostics regulatory clearances proves the level of careful data collection and hard clinical evidence you need for any AI diagnostic. Cleerly, which uses AI to analyze CT angiography for heart disease, is in a similar boat where precision and constant improvement are the name of the game. Their tech, by its nature, needs a way to handle efficient, pre-approved changes. The FDA’s PCCP guidance is a direct answer to the problems these companies face when they want to refine models with new data or expand what their software can do. Can you write a clear PCCP? That’s going to be a huge competitive differentiator. When investors do their technical due diligence, they won’t just look at the initial 510(k) anymore. They’ll dig into the company’s plan for managing algorithmic drift and continuous improvement inside that pre-approved regulatory envelope. A solid PCCP shows you have a mature regulatory strategy and won’t get buried in regulatory debt down the line.

PCCPs as a Regulatory Moat: Cutting Post-Market Costs

For VCs focused on regulation, PCCPs create a huge competitive advantage, a real regulatory moat. The framework makes investing in SaMD companies, particularly those with adaptive AI, far less risky. The benefits are clear:

• Faster Enhancements: The most obvious win is how fast you can deploy algorithmic improvements. You’re not waiting months for another regulatory review. You can push updates quickly, responding to clinical needs or what competitors are doing. In a field moving as fast as AI health, that agility is gold.
• Predictable Path: PCCPs give you a predictable regulatory road for post-market changes. That predictability is worth a fortune for strategic planning and keeping investors happy. It lets companies forecast their regulatory timelines and costs with some real accuracy, instead of gambling on repeated 510(k)s.
• Lasting Advantage: A company with a good PCCP can keep improving its product’s accuracy and features while staying compliant. That iterative cycle makes it tough for new competitors to catch up if they don’t have a similar plan for their own adaptive algorithms. This strengthens the company’s data moat, since its proprietary data can fuel model improvements without getting stuck in regulatory limbo.
• Better Resource Use: The paperwork and cost for repeated premarket submissions are massive. PCCPs simplify the process, freeing up engineering and regulatory staff to work on actual innovation, market expansion, or more clinical studies. Getting a PCCP isn’t a rubber stamp, though. The FDA’s final guidance spells out specific eligibility criteria you have to meet. There are three big parts: a “Description of Modifications” (the specific changes you plan to make), a “Modification Protocol” (how you’ll implement and validate them with pre-set acceptance criteria), and an “Impact Assessment” (the risks and benefits of the changes). Your company better have a strong quality management system (QMS), probably ISO 13485-certified, and follow Good Machine Learning Practice (GMLP) to prove your learning algorithms are safe and effective.
  

  Methodology and Source Note

  This analysis comes from our own deep-dive into the FDA’s December 2024 final guidance on Predetermined Change Control Plans, combined with a review of operational regulatory policy. We’ve used examples from real AI health companies to show what this means in practice. This information is current as of August 31, 2026. The FDA’s device center (CDRH) is leading this work, and they clearly get the unique issues that come with AI/ML in medicine. Their proactive work on PCCPs shows the regulatory environment is finally catching up to the technology. This isn’t just a procedural tweak. It’s a strategic change that will define the winners and losers in AI health for the next several years.